ATXI vs COLL vs PCRX vs SUPN vs PRGO

For growth investors, Collegium Pharmaceutical, Inc.

(COLL) is the stronger pick with 23. 6% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Collegium Pharmaceutical, Inc. (COLL) offers the better valuation at 22. 7x trailing P/E (5. 4x forward), making it the more compelling value choice. Analysts rate Collegium Pharmaceutical, Inc. (COLL) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Collegium Pharmaceutical, Inc.

(COLL) is the cheapest at 22. 7x versus Pacira BioSciences, Inc. at 147. 8x. On forward P/E, Collegium Pharmaceutical, Inc. is actually cheaper at 5. 4x.

Over the past 5 years, Supernus Pharmaceuticals, Inc.

(SUPN) delivered a total return of +78. 0%, compared to -100. 0% for Avenue Therapeutics, Inc. (ATXI). Over 10 years, the gap is even starker: SUPN returned +228. 4% versus ATXI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Avenue Therapeutics, Inc.

(ATXI) is the lower-risk stock at -0. 11β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately -1175% more volatile than ATXI relative to the S&P 500. On balance sheet safety, Supernus Pharmaceuticals, Inc. (SUPN) carries a lower debt/equity ratio of 4% versus 3% for Collegium Pharmaceutical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Collegium Pharmaceutical, Inc.

(COLL) is pulling ahead at 23. 6% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Pacira BioSciences, Inc. grew EPS 107. 4% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, COLL leads at 18. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Collegium Pharmaceutical, Inc.

(COLL) is the more profitable company, earning 8. 1% net margin versus -266. 7% for Avenue Therapeutics, Inc. — meaning it keeps 8. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: COLL leads at 24. 0% versus -279. 8% for ATXI. At the gross margin level — before operating expenses — ATXI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Collegium Pharmaceutical, Inc.

(COLL) trades at 5. 4x forward P/E versus 24. 1x for Supernus Pharmaceuticals, Inc. — 18. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

In this comparison, PRGO (9.

8% yield) pays a dividend. ATXI, COLL, PCRX, SUPN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Avenue Therapeutics, Inc.

(ATXI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 11)). Both have compounded well over 10 years (ATXI: -100. 0%, PRGO: -77. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ATXI is a small-cap quality compounder stock; COLL is a small-cap high-growth stock; PCRX is a small-cap quality compounder stock; SUPN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock. PRGO pays a dividend while ATXI, COLL, PCRX, SUPN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.